PRACTICE OF EPIDEMIOLOGY |
Analytic Strategies to Adjust Confounding using Exposure Propensity Scores and Disease Risk Scores: Nonsteroidal Antiinflammatory Drugs and Short-term Mortality in the Elderly
1 Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
2 Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Correspondence to Dr. Til Stürmer, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120 (e-mail: til.sturmer{at}post.harvard.edu).
Little is known about optimal application and behavior of exposure propensity scores (EPS) in small studies. In a cohort of 103,133 elderly Medicaid beneficiaries in New Jersey, the effect of nonsteroidal antiinflammatory drug use on 1-year all-cause mortality was assessed (1995–1997) based on the assumption that there is no protective effect and that the preponderance of any observed effect would be confounded. To study the comparative behavior of EPS, disease risk scores, and "conventional" disease models, the authors randomly resampled 1,000 subcohorts of 10,000, 1,000, and 500 persons. The number of variables was limited in disease models, but not EPS and disease risk scores. Estimated EPS were used to adjust for confounding by matching, inverse probability of treatment weighting, stratification, and modeling. The crude rate ratio of death was 0.68 for users of nonsteroidal antiinflammatory drugs. "Conventional" adjustment resulted in a rate ratio of 0.80 (95% confidence interval: 0.77, 0.84). The rate ratio closest to 1 (0.85) was achieved by inverse probability of treatment weighting (95% confidence interval: 0.82, 0.88). With decreasing study size, estimates remained further from the null value, which was most pronounced for inverse probability of treatment weighting (n = 500: rate ratio = 0.72, 95% confidence interval: 0.26, 1.68). In this setting, analytic strategies using EPS or disease risk scores were not generally superior to "conventional" models. Various ways to use EPS and disease risk scores behaved differently with smaller study size.
anti-inflammatory agents, non-steroidal; bias (epidemiology); cohort studies; confounding factors (epidemiology); epidemiologic methods; research design
Abbreviations: DRS, disease risk score; EPS, exposure propensity score; IPTW, inverse probability of treatment weighting; NSAID, nonsteroidal antiinflammatory drug
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. G Arbogast and W. A Ray Use of disease risk scores in pharmacoepidemiologic studies Statistical Methods in Medical Research, February 1, 2009; 18(1): 67 - 80. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Cummings Propensity Scores Arch Pediatr Adolesc Med, August 1, 2008; 162(8): 734 - 737. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mongelluzzo, Z. Mohamad, T. R. Ten Have, and S. S. Shah Corticosteroids and Mortality in Children With Bacterial Meningitis JAMA, May 7, 2008; 299(17): 2048 - 2055. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Schmoor, A. Caputo, and M. Schumacher Evidence from Nonrandomized Studies: A Case Study on the Estimation of Causal Effects Am. J. Epidemiol., May 1, 2008; 167(9): 1120 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. Brekke, T. Omland, S. H. Holmedal, P. Smith, and V. Soyseth Troponin T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation Eur. Respir. J., March 1, 2008; 31(3): 563 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Sturmer, S. Schneeweiss, K. J. Rothman, J. Avorn, and R. J. Glynn Performance of Propensity Score Calibration--A Simulation Study Am. J. Epidemiol., May 15, 2007; 165(10): 1110 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sturmer, J. E. Buring, I-M. Lee, J. M. Gaziano, and R. J. Glynn Metabolic Abnormalities and Risk for Colorectal Cancer in the Physicians' Health Study Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2391 - 2397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Avorn Dangerous deception -- hiding the evidence of adverse drug effects. N. Engl. J. Med., November 23, 2006; 355(21): 2169 - 2171. [Full Text] [PDF]
|
|
|
|
|
|
T. Kurth, A. M. Walker, R. J. Glynn, K. A. Chan, J. M. Gaziano, K. Berger, and J. M. Robins Results of Multivariable Logistic Regression, Propensity Matching, Propensity Adjustment, and Propensity-based Weighting under Conditions of Nonuniform Effect Am. J. Epidemiol., February 1, 2006; 163(3): 262 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Ray Observational studies of drugs and mortality. N. Engl. J. Med., December 1, 2005; 353(22): 2319 - 2321. [Full Text] [PDF]
|
|
|
|
|
|
T. Sturmer, S. Schneeweiss, J. Avorn, and R. J. Glynn Adjusting Effect Estimates for Unmeasured Confounding with Validation Data using Propensity Score Calibration Am. J. Epidemiol., August 1, 2005; 162(3): 279 - 289. [Abstract] [Full Text] [PDF]
|
|